Elicio Therapeutics (ELTX) Cash from Operations (2020 - 2026)
Elicio Therapeutics posted quarterly Cash from Operations of 11645000.0 for Q1 2026, down 15.08% year-on-year from 13712993.72 in Q1 2025, and down 71.33% on a QoQ basis from 6797000.0 in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Cash from Operations data on file, last reported at 11645000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 15.08% year-over-year to 11645000.0; the trailing twelve-month figure through Mar 2026 stood at 38478000.0 (down 9.73% YoY), and the FY2025 full-year result was 36952000.0, changed 0.31% from the prior year.
- Cash from Operations for Q1 2026 stood at 11645000.0, down from 6797000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 6136000.0 in Q2 2022 and bottomed at 15653000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 8928000.0 (2024), against an average of 8266941.18.
- The widest annual swing landed in 2022, when Cash from Operations soared 158.27%; it then sank 254.42% in 2023.
- A 5-year view of Cash from Operations shows it stood at 7276000.0 in 2022, then slumped by 36.0% to 9895000.0 in 2023, then rose by 11.63% to 8744000.0 in 2024, then rose by 22.27% to 6797000.0 in 2025, then slumped by 71.33% to 11645000.0 in 2026.
- The last three Cash from Operations figures came in at 11645000.0 (Q1 2026), 6797000.0 (Q4 2025), and 11086000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -11.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.65 Mn |
| Mar 31, 2026 | -11.65 Mn |
| Dec 31, 2025 | -6.80 Mn |
| Dec 31, 2025 | -6.80 Mn |
| Sep 30, 2025 | -11.09 Mn |
| Sep 30, 2025 | -11.09 Mn |
| Jun 30, 2025 | -8.95 Mn |
| Jun 30, 2025 | -8.95 Mn |
| Mar 31, 2025 | -10.12 Mn |
| Mar 31, 2025 | -10.12 Mn |
| Dec 31, 2024 | -8.74 Mn |
| Dec 31, 2024 | -8.74 Mn |
| Sep 30, 2024 | -7.27 Mn |
| Sep 30, 2024 | -7.27 Mn |
| Jun 30, 2024 | -8.93 Mn |
| Jun 30, 2024 | -8.93 Mn |
| Mar 31, 2024 | -12.12 Mn |
| Mar 31, 2024 | -12.12 Mn |
| Dec 31, 2023 | -9.90 Mn |
| Dec 31, 2023 | -9.90 Mn |
| Sep 30, 2023 | -5.19 Mn |
| Sep 30, 2023 | -5.19 Mn |
| Jun 30, 2023 | -9.48 Mn |
| Jun 30, 2023 | -9.48 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Dec 31, 2022 | -7.28 Mn |
| Dec 31, 2022 | -7.28 Mn |
| Sep 30, 2022 | -5.39 Mn |
| Sep 30, 2022 | -5.39 Mn |
| Jun 30, 2022 | 6.14 Mn |
| Jun 30, 2022 | 6.14 Mn |
| Mar 31, 2022 | -15.65 Mn |
| Mar 31, 2022 | -15.65 Mn |
| Dec 31, 2021 | -14.36 Mn |
| Dec 31, 2021 | -14.36 Mn |
| Sep 30, 2021 | -15.20 Mn |
| Sep 30, 2021 | -15.20 Mn |
| Jun 30, 2021 | -10.53 Mn |
| Jun 30, 2021 | -10.53 Mn |
| Mar 31, 2021 | -12.55 Mn |
| Mar 31, 2021 | -12.55 Mn |
| Dec 31, 2020 | 20.59 Mn |
| Dec 31, 2020 | 20.59 Mn |
| Sep 30, 2020 | -21.94 Mn |
| Sep 30, 2020 | -21.94 Mn |
| Jun 30, 2020 | -12.80 Mn |
| Jun 30, 2020 | -12.80 Mn |
| Mar 31, 2020 | -8.73 Mn |
| Mar 31, 2020 | -8.73 Mn |